Evaluation of new indole and bromoindole derivatives as pp60 c-Src tyrosine kinase inhibitors

Chemical Biology and Drug Design

Volumn 74, Issue 4, 2009, Pages 397-404

  Kiliç, Zühal ^a   I̧gör, Yasemin G ^b   Ölgen, Süreyya ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

Indole and bromoindole derivatives; Inhibition of pp60c Src; Schiff bases; Synthesis; Tyrosine kinase

Indexed keywords

1 (1 BENZYL 1H INDOLE 3 YL) N (2,4 DICHLOROBENZYL)METHANAMINE; 1 (1 BENZYL 1H INDOLE 3 YL) N (2,4 DIFLUOROBENZYL)METHANAMINE; 1 (1 BENZYL 1H INDOLE 3 YL) N (4 CHLOROBENZYL)METHANAMINE; 1 (1 BENZYL 1H INDOLE 3 YL) N (4 FLUOROROBENZYL)METHANAMINE; 1 (1 BENZYL 1H INDOLE 3 YL) N BENZYLMETHANAMINE; 1 (1 BENZYL 5 BROMO 1H INDOLE 3 YL) N (2,4 DICHLOROBENZYL)METHANAMINE; 1 (1 BENZYL 5 BROMO 1H INDOLE 3 YL) N (2,4 DIFLUOROBENZYL)METHANAMINE; 1 (1 BENZYL 5 BROMO 1H INDOLE 3 YL) N (4 CHLOROBENZYL)METHANAMINE; 1 (1 BENZYL 5 BROMO 1H INDOLE 3 YL) N (4 FLUOROBENZYL)METHANAMINE; 1 (1 BENZYL 5 BROMO 1H INDOLE 3 YL) N BENZYLMETHANAMINE; 2 [(1 BENZYL 5 BROMO 1H INDOLE 3 YL)METHYLENE] 1 (2,4 DICHLOROPHENYL)METHANAMINE; 2 [(1 BENZYL 5 BROMO 1H INDOLE 3 YL)METHYLENE] 1 (2,4 DIFLUOROPHENYL)METHANAMINE; 2 [(1 BENZYL 5 BROMO 1H INDOLE 3 YL)METHYLENE] 1 (4 CHLOROPHENYL)METHANAMINE; 2 [(1 BENZYL 5 BROMO 1H INDOLE 3 YL)METHYLENE] 1 (4 FLUOROPHENYL)METHANAMINE; 2 [(1 BENZYL 5 BROMO 1H INDOLE 3 YL)METHYLENE] 1 PHENYLMETHANAMINE; BROMOINDOLE DERIVATIVE; INDOLE DERIVATIVE; N [(1 BENZYL 1H INDOLE 3 YL)METHYLENE] 1 (2,4 DICHLOROPHENYL)METHANAMINE; N [(1 BENZYL 1H INDOLE 3 YL)METHYLENE] 1 (2,4 DIFLUOROPHENYL)METHANAMINE; N [(1 BENZYL 1H INDOLE 3 YL)METHYLENE] 1 (4 CHLOROPHENYL)METHANAMINE; N [(1 BENZYL 1H INDOLE 3 YL)METHYLENE] 1 (4 FLUOROPHENYL)METHANAMINE; N [(1 BENZYL 1H INDOLE 3 YL)METHYLENE] 1 PHENYLMETHANAMINE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; IC 50; PRIORITY JOURNAL; REDUCTION; SUBSTITUTION REACTION;

IMINES; INDOLES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS PP60(C-SRC); SCHIFF BASES;

EID: 70349131234     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2009.00876.x     Document Type: Article

References (36)

1. c-src protein tyrosine kinase inhibitors. Biopolymers 59 : 167 179.
2. Ingley E. (2008) Src family kinases: Regulation of their activities, levels and identification of new pathways. Biochemica et Biophysica Acta 1784 : 56 65.
3. Alvarez R.H., Kantarjian H.M., Cortes J.E. (2006) The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 107 : 1918 1929.
4. Hu G., Place A.T., Minshall R.D. (2008) Regulation of endothelial permeability by src kinase signaling: vascular leakage versus transcellular transport of drugs and macromolecules. Chem Biol Interact 171 : 177 189.
5. Nam N.H., Lee S., Ye G., Sun G., Parang K. (2004) ATP-phosphopeptide conjugates as inhibitors of src tyrosine kinases. Bioorg Med Chem 12 : 5753 5766.
6. Bridges A.J. (2001) Chemical inhibitors of protein kinases. Chem Rev 101 : 2541 2571.
7. Chong Y., Kuia K., Mulherin T.D., Cheng H. (2005) Endogenous and synthetic inhibitors of the src-family protein tyrosine kinases. Biochim Biophys Acta 1754 : 210 220.
8. Belsches-Jablonski A.P., Demory M.L., Parsons J.T., Parsons S.J. (2005) The src pathway as a therapeutic strategy. Drug Discovery Today: Therapeutic Strategies 2 : 313 321.
9. Frame M.C. (2002) Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 1602 : 114 130.
10. Susa M., Missbach M., Green J. (2000) Src inhibitors: drugs for the treatment of osteoporosis, cancer or both?. TIPS 21 : 489 495.
11. Cohen D.M. (2005) Src family kinases in cell volume regulation. Am J Physiol Cell Physiol 288 : C483 C493.
12. Furumoto Y., Gomez G., Gonzales-Espinosa C., Kovaroya M., Odom S., Ryan J.J., Rivera J. (2005) The role of Src family kinases in mast cell effector function. Novartis Found Symp 271 : 39 47.
13. Homsi J., Cubitt C., Daud A. (2007) The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets 11 : 91 100.
14. Zhou J., Leonard M., Van Bockstaele E., Menko A.S. (2007) Mechanism of Src kinase induction of cortical cataract following exposure to stress: destabilization of cell-cell junctions. Mol Vis 13 : 1298 1310.
15. Warmuth M., Damoiseaux R., Liu Y., Fabbro D., Gray N. (2003) Src family kinases: potential targets for the treatment of human cancer and leukemia. Curr Pharm Des 9 : 2043 2059.
16. Zhu X., Kim J.L., Newcomb J.R., Rose P.E., Stover D.R., Toledo L.M., Zhao H., Morgenstern K.A. (1999) Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure 7 : 651 661.
17. Blake R.A., Broome M.A., Liu X., Wu J., Gishizky M., Sun L., Courtneidge S.A. (2000) SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 20 : 9018 9027.
18. Guan H., Laird A.D., Blake R.A., Tang C., Liang C. (2004) Design and synthesis of aminopropyl tetrahydroindole-based indolin-2-ones as selective and potent inhibitors of src and yes tyrosine kinases. Bioorg Med Chem Lett 14 : 187 190.
19. c-Src tyrosine kinase. Part 2: hydroxyindole derivatives. Bioorg Med Chem Lett 10 : 483 486.
20. c-src receptor tyrosine kinase and investigation of the inhibition using receptor docking studies. J Enzyme Inhib Med Chem 18 : 485 490.
21. c-src receptor tyrosine kinase with the application of receptor docking studies. Farmaco 60 : 497 506.
22. c-src tyrosine kinase: synthesis and biological activity. Chem Biol Drug Des 30 : 715 718.
23. c-Src tyrosine kinase inhibitory activities of novel indole-3-imine and amine derivatives substituted at N1 and C5. Arch PharmChem Life Sci 342 : 333 343.
24. Pitala V., Romeo G., Materia L., Salerno L., Siracusa M.A., Modica M., Mereghetti I., Cagnotto A., Russo F. (2005) Novel (E)-alpha-[(1H-indol-3-yl) methylene]benzeneacetic acids as endothelin receptor ligands. Farmaco 60 : 731 738.
25. Everett S.A., Naylor M.A., Stratford M.R.L., Patel K.B., Ford E., Mortensen A., Ferguson A.C., Vojnovic B., Wardman P. (2001) Iminoxyl radicals and stable products from the one-electron oxidation of 1-methylindole-3- carbaldehyde oximes. J Chem Soc Perkin Trans 2 : 1989 1997.
26. Mahboobi S., Grothus G., Meind W. (1994) Antimykobakteriell wirksame indolderivative. Arch Pharm 327 : 105 114.
27. Alemany A., Alvarez E.F., Martinez-Lopez J.M. (1975) Enzyme inhibitors. XV. Preparation of 3-(propargylaminomethyl)indoles. Bull Soc Chim Fr 5-6 : 1223 1227.
28. Alemany A., Alvarez E.F., Martinez-Lopez J.M. (1975) Enzymic inhibitors. XVI. Preparation and study of 1-alkyl-3-(propargylaminomethyl)indoles as inhibitors of monoamine oxidase. Anales de Quimica 71 : 512 518.
29. Taylor V.C., Buckley C.D., Douglas M., Cody A.J., Simmons D.L., Freeman S.D. (1999) The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J Biol Chem 274 : 11505 11512.
30. Harayama T., Hori A., Abe H., Yasuo T. (2004) Concise synthesis of pyrrolophenanthridine alkaloids using a Pd-mediated biaryl coupling reaction with regioselective C-H activation via the intramolecular coordination of the amine to Pd. Tetrahedron 60 : 1611 1616.
31. Gribble G.W., Hoffman J.H. (1977) Reactions of sodium borohydride in acidic media; VI. Reduction of indoles with cyanoborohydride in acetic acid. Synthesis 12 : 859 860.
32. Elokdah H., Abou-Gharbia M., Hennan J.K., McFarlane G., Mugford C.P., Krishnamurty G., Crandall D.L. (2004) Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J Med Chem 47 : 3491 3494.
33. Moody C., Ward J.G. (1984) [2,3] Fused indoles. Part 2. Synthesis of 1,8-dihydropyrrolo[2,3-b]indoles, and photochemical rearrangement of their 1-allyl derivatives. J Chem Soc Perkin Trans 1 : 2903 2909.
34. Kurihara T., Fujimoto T., Harusawa S., Ryuji Y. (1987) Simple N-alkylation and N-acylation of 3-acetylindole and 3-indolecarboxaldehyde. Synthesis 4 : 396 397.
35. Dubey P.K., Babu B., Narayana M.V. (2006) Synthesis of N-alkyl/aralkyl derivatives of indole-3-aldehydes using TEBAC as phase transfer catalyst. J Heterocycl chem 15 : 205 208.
36. c-Src tyrosine kinase inhibitors. Arch Der Pharm 341 : 113 120.